Dermatological Cosmetic Composition Comprising an SDKP Peptide or an Analog Thereof

A lipid nanoparticle comprising:

• a core consisting of a lipid phase (L1);
• at least one surfactant comprising a hydrophilic portion and a lipophilic portion;
• an internal membrane surrounding said core consisting of a lipid phase (L2), comprising the lipophilic portion of said surfactant;
• an external membrane, surrounding said internal membrane, consisting of an aqueous phase (A1) comprising the hydrophilic portion of said surfactant;
• and
• at least one peptide conjugate, comprising a peptide strand of formula SDKP, or a biological peptide analog thereof, wherein at least one linear or branched, saturated or unsaturated C3-C50 fatty chain is grafted at the N- and/or C-terminal end of the peptide strand, and said peptide conjugate is such that its lipophilic portion is in the lipid phase L2 and its hydrophilic portion is in the phase A1.

A nanoemulsion comprising:

• at least one dispersed lipid phase (L3), and
• at least one continuous aqueous phase (A2) wherein the aqueous phase comprises at least one surfactant, wherein,
• at the interface between the aqueous phase (A2) and the lipid phase (L1), there is at least one peptide conjugate comprising a peptide strand of formula SDKP, or a biological peptide analog thereof, wherein at least one linear or branched, saturated or unsaturated, C13-C50 fatty chain is grafted at the N- and/or C-terminal end of the peptide strand and/or in that said nanoemulsion comprises at least one lipid nanoparticle comprising
• a core consisting of a lipid phase (L1);
• at least one surfactant comprising a hydrophilic portion and a lipophilic portion;
• an internal membrane surrounding said core consisting of a lipid phase (L2), comprising the lipophilic portion of said surfactant;
• an external membrane, surrounding said internal membrane, consisting of an aqueous phase (A1) comprising the hydrophilic portion of said surfactant;
• and
• at least one peptide conjugate, comprising a peptide strand of formula SDKP, or a biological peptide analog thereof, wherein at least one linear or branched, saturated or unsaturated C3-C50 fatty chain is grafted at the N- and/or C-terminal end of the peptide strand, and said peptide conjugate is such that its lipophilic portion is in the lipid phase L2 and its hydrophilic portion is in the phase A1 wherein optionally the lipids of (L1) and (L3), or (L2) and (L3) are identical.

A method for restructuring or preserving the appearance of the skin of a human subject comprising a step of applying on the skin a lipid nanoparticle comprising:

• a core consisting of a lipid phase (L1);
• at least one surfactant comprising a hydrophilic portion and a lipophilic portion;
• an internal membrane surrounding said core consisting of a lipid phase (L2), comprising the lipophilic portion of said surfactant;
• an external membrane, surrounding said internal membrane, consisting of an aqueous phase (A1) comprising the hydrophilic portion of said surfactant;
• and
• at least one peptide conjugate, comprising a peptide strand of formula SDKP, or a biological peptide analog thereof, wherein at least one linear or branched, saturated or unsaturated C3-C50 fatty chain is grafted at the N- and/or C-terminal end of the peptide strand, and said peptide conjugate is such that its lipophilic portion is in the lipid phase L2 and its hydrophilic portion is in the phase A1.

A method for restructuring or preserving the appearance of the skin of a human subject comprising a step of applying on the skin a nanoemulsion comprising:

• at least one dispersed lipid phase (L3), and
• at least one continuous aqueous phase (A2) wherein the aqueous phase comprises at least one surfactant, wherein, at the interface between the aqueous phase (A2) and the lipid phase (L1), there is at least one peptide conjugate comprising a peptide strand of formula SDKP, or a biological peptide analog thereof, wherein at least one linear or branched, saturated or unsaturated, C13-C50 fatty chain is grafted at the N- and/or C-terminal end of the peptide strand and/or in that said nanoemulsion comprises at least one lipid nanoparticle comprising:
• a core consisting of a lipid phase (Li);
• at least one surfactant comprising a hydrophilic portion and a lipophilic portion;
• an internal membrane surrounding said core consisting of a lipid phase (L2), comprising the lipophilic portion of said surfactant;
• an external membrane, surrounding said internal membrane, consisting of an aqueous phase (A1) comprising the hydrophilic portion of said surfactant;
• and at least one peptide conjugate, comprising a peptide strand of formula SDKP, or a biological peptide analog thereof, wherein at least one linear or branched, saturated or unsaturated C3-C50 fatty chain is grafted at the N-and/or C-terminal end of the peptide strand, and said peptide conjugate is such that its lipophilic portion is in the lipid phase L2 and its hydrophilic portion is in the phase A1. wherein optionally the lipids of (L1) and (L3), or (L2) and (L3) are identical.

A method for restructuring or preserving the appearance of the skin of a human subject comprising a step of applying on the skin a cosmetic formulation comprising one or more lipid nanoparticles comprising:

• a core consisting of a lipid phase (L1);
• at least one surfactant comprising a hydrophilic portion and a lipophilic portion;
• an internal membrane surrounding said core consisting of a lipid phase (L2), comprising the lipophilic portion of said surfactant;
• an external membrane, surrounding said internal membrane, consisting of an aqueous phase (A1) comprising the hydrophilic portion of said surfactant;
• and
• at least one peptide conjugate comprising a peptide strand of formula SDKP, or a biological peptide analog thereof, wherein at least one linear or branched, saturated or unsaturated C3-C50 fatty chain is grafted at the N- and/or C-terminal end of the peptide strand, and said peptide conjugate is such that its lipophilic portion is in the lipid phase L2 and its hydrophilic portion is in the phase A1.